Intercept skyrockets 281% on NASH results
This article was originally published in Scrip
Intercept Pharmaceuticals nearly tripled its stock value on 9 January when the New York-based company reported that a Phase II clinical trial for obeticholic acid (OCA) in the treatment of nonalcoholic steatohepatitis (NASH) was stopped early, because the primary endpoint was met in an interim analysis.
You may also be interested in...
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.